Business Context and Reporting Period
Clover Health Investments, Corp. filed this Form 8-K on January 7, 2021, with the report signed January 12, 2021. The filing reports the closing of the domestication and business combination with Social Capital Hedosophia Holdings Corp. III and Clover Health Investments, Corp. The predecessor SPAC ceased to be a shell company, and the combined company adopted the name Clover Health Investments, Corp.
The filing is primarily a transaction and corporate-governance disclosure. It does not provide a new quarterly or annual operating-results period. Historical financial statements and pro forma information are incorporated from the proxy statement and Exhibit 99.1.
Key Financial and Capitalization Metrics
- Merger consideration: Clover stockholders received aggregate consideration of approximately $499.8 million in cash and 260.97 million shares of Class B common stock valued at $10.00 per share. The actual cash/stock ratio was 32.3%.
- PIPE financing: Clover issued 40.0 million shares of Class A common stock for aggregate proceeds of $400.0 million, including 15.5 million shares purchased by sponsor-related investors.
- Trust account and redemptions: Public holders redeemed 24,892 shares for approximately $249,000, at $10.0141613 per share. The trust account held approximately $827.9 million immediately before closing and funded the cash merger consideration.
- Post-closing securities: Immediately after the transactions and PIPE investment, 143.48 million Class A shares, 260.97 million Class B shares, and 38.53 million warrants were outstanding.
- Voting structure: Class A shares carry one vote per share and Class B shares carry 10 votes per share. Clover stockholders held approximately 64.5% of outstanding common stock and 94.8% of voting power immediately after closing.
- Liquidity, revenue, profit, cash flow, margins and debt: The filing does not provide clear current-period values for revenue, net income or loss, operating cash flow, margins, debt, or post-closing cash beyond the trust-account and PIPE amounts described above.
Material Changes Versus the Prior Comparable Period
- SCH domesticated from a Cayman Islands entity into a Delaware corporation and changed its name to Clover Health Investments, Corp.
- The merger created Clover Health as the surviving public company and resulted in the combined company listing Class A common stock and warrants on Nasdaq under CLOV and CLOWW.
- The company replaced SCH’s former public securities, which had traded on the New York Stock Exchange under IPOC, IPOC.W and IPOC.U.
- Marcum LLP was dismissed after completing the audit of the predecessor SPAC’s 2020 financial statements, and Ernst & Young LLP was appointed to audit the combined company for 2021. The filing reports no disagreements or reportable events with Marcum.
- The company entered into amended registration rights arrangements, new director and officer indemnification agreements, and new equity compensation and incentive plans.
Guidance, Outlook, Commentary, Risks and Unusual Items
- The filing provides no formal financial guidance or quantified operating outlook.
- Management’s forward-looking statements address expected results, cash flows, growth, market opportunity, expansion of the member and provider bases, adoption of the Clover Assistant platform, and anticipated benefits of the business combination.
- Principal risks include competition, execution of the merger benefits, Nasdaq listing and trading liquidity, growth management, expansion into new markets, employee recruitment and retention, intellectual property protection, COVID-19 effects, general economic conditions, and geopolitical uncertainty.
- Significant unusual items include the $400.0 million PIPE financing, the cash and stock merger consideration, the dual-class voting structure, and substantial performance-based equity awards for senior executives.
- Executive equity awards include performance hurdles generally tied to sustained volume-weighted average stock prices ranging from $20 to $30 per share and service requirements extending up to five years. The Management Incentive Plan authorizes up to 33.43 million Class B shares, while the 2020 Equity Incentive Plan authorizes up to 30.64 million Class A shares.
- Registration rights include resale rights for specified holders and lock-ups that generally end on the earlier of 180 days after closing or the satisfaction of specified stock-price conditions.
- The company had not paid cash dividends and stated that future dividends would depend on revenues, earnings, capital requirements, financial condition and board discretion.
Most Important Facts an Investor Should Verify
- Review Exhibit 99.1 and the incorporated proxy-statement financials for actual revenue, losses, cash flows, cash balances, liabilities, medical costs and pro forma results.
- Confirm the final post-closing share count, warrant count, dilution from executive awards, and the effects of the dual-class voting structure.
- Assess the use of the approximately $827.9 million trust balance, including the approximately $499.8 million cash merger consideration and transaction expenses.
- Review the PIPE subscription agreements, registration rights, lock-up terms and potential resale overhang.
- Evaluate executive compensation, performance-based vesting hurdles and change-in-control acceleration provisions.
- Review the incorporated risk factors, particularly Medicare-related regulatory exposure, COVID-19 effects, competition, platform adoption and the company’s ability to achieve projected growth.
- Confirm the transition from Marcum to Ernst & Young and review the predecessor auditor’s going-concern explanatory paragraph.